Related Experiment Video
Updated: Jul 21, 2025
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Toward the clinical development of synthetic immunity to cancer
Julie M Garcia1,2,3,4,5,6,7, Cassandra E Burnett1,2,3,4,5,6,7, Kole T Roybal1,2,3,4,5,6,7
1Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA.
Abstract:
Synthetic biology (synbio) tools, such as chimeric antigen receptors (CARs), have been designed to target, activate, and improve immune cell responses to tumors. These therapies have demonstrated an ability to cure patients with blood cancers. However, there are significant challenges to designing, testing, and efficiently translating these complex cell therapies for patients who do not respond or have immune refractory solid tumors. The rapid progress of synbio tools for cell therapy, particularly for cancer immunotherapy, is encouraging but our development process should be tailored to increase translational success. Particularly, next-generation cell therapies should be rooted in basic immunology, tested in more predictive preclinical models, engineered for potency with the right balance of safety, educated by clinical findings, and multi-faceted to combat a range of suppressive mechanisms. Here, we lay out five principles for engineering future cell therapies to increase the probability of clinical impact, and in the context of these principles, we provide an overview of the current state of synbio cell therapy design for cancer. Although these principles are anchored in engineering immune cells for cancer therapy, we posit that they can help guide translational synbio research for broad impact in other disease indications with high unmet need.
Insights
Synthetic biology (synbio) tools like chimeric antigen receptors (CARs) show promise for blood cancers but face challenges in treating solid tumors. Future cell therapies need improved design, preclinical testing, and multifaceted strategies for greater clinical success.
Area of Science:
- Synthetic biology applications in immunology and cell therapy.
- Cancer immunotherapy and next-generation cell engineering.
Background:
- Synthetic biology (synbio) tools, including chimeric antigen receptors (CARs), are engineered to enhance immune cell responses against tumors.
- Current CAR-based cell therapies have shown success in treating hematologic malignancies but face significant hurdles in solid tumor treatment.
Purpose of the Study:
- To address challenges in translating synthetic biology cell therapies for solid tumors.
- To propose five guiding principles for engineering future cell therapies to enhance clinical impact.
Main Methods:
- Reviewing the current state of synthetic biology cell therapy design for cancer.
- Outlining principles for future cell therapy development rooted in immunology and preclinical modeling.
- Discussing strategies for balancing potency and safety in engineered immune cells.
Main Results:
- Identified challenges in the design, testing, and translation of cell therapies for immune-refractory solid tumors.
- Proposed five principles to guide the development of next-generation cell therapies.
- Highlighted the need for multi-faceted approaches to overcome tumor suppressive mechanisms.
Conclusions:
- Synthetic biology offers powerful tools for cancer immunotherapy, but translational success requires a refined development process.
- The proposed principles aim to increase the clinical impact of engineered immune cell therapies.
- These principles may also guide translational synthetic biology research for other diseases with unmet needs.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:28Preclinical Development: Overview
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...